Gilead sciences to pay Merck $2.54 billion in hepatitis c royalties: court verdict

(Reuters) - A federal jury in Delaware on Thursday awarded Merck & Co $2.54 billion in royalties in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.